Payers
Solutions That Are Innovative and Cost-effective
At Bioventus, we understand that in today’s healthcare climate, cost-control has become more critical than ever. We’re focused on bringing innovations for active healing technology to the forefront of medicine, providing cost-effective therapies for patients requiring bone fusion or osteoarthritic joint pain relief.
We have a team of specialists with both medical and payer backgrounds who are ready to work directly with payers regarding reimbursement, products and our capabilities.
Biologics: A New Frontier
Cost-effective Treatment Alternatives to More Invasive Procedures
At Bioventus, we have a different approach to bone health that doesn’t involve drugs or surgery. Rather than simply wait for the body to naturally heal itself, we provide active orthopaedic solutions that stimulate the body’s natural healing process, providing therapies that are easily administered either at the patient’s home or in the doctor’s office. Our products work with the body, enhancing the body’s natural healing processes while accelerating recovery without the need for costly, more invasive procedures.
Minimizing Costs While Delivering a Higher Quality of Care
Treatment Options as Cost-effective Alternatives with Bioventus Active Healing Therapies and Bioventus Surgical
At Bioventus, our goal is to pioneer new treatments rooted in biology – safe, innovative, effective solutions that help patients return to their regular lives. By speeding recovery time while providing less invasive care options when possible, costs can be kept down without sacrificing the high quality of care the patient receives.
Heal Non-union* Fractures Without Surgery
If a patient is dealing with bone fracture that simply isn’t healing, then surgery might be called for, in order to implant plates and screws to help the bone start healing. Before considering this option, patients are increasingly turning to the cost-effective EXOGEN Ultrasound Bone Healing System, the only FDA-approved ultrasound product that has demonstrated the ability to accelerate fracture healing.
EXOGEN is a clinically proven alternative therapy to surgery in healing non-union fractures with an 86%1 heal rate. With non-union fracturing healing through use of EXOGEN, both patients and insurance companies avoid having to consider surgical options, with costs that can be in excess of $20,000. While some may initially balk at EXOGEN’s price tag, studies show that EXOGEN has the lowest expected cost ($6,610)2 among bone stimulators.
For more information about how EXOGEN® can be the perfect alternative to surgery, visit the EXOGEN website.
BONES Studies Information
Announced in March 2017, Bioventus has commissioned an innovative series of clinical studies to further validate the ability of the EXOGEN® Ultrasound Bone Healing System to mitigate the risk of a fracture progressing to nonunion in the presence of known risk factors. Learn more
Non-surgical Pain Relief for Patients Suffering from Osteoarthritis
When osteoarthritis strikes at joints like the knee, the synovial fluid that keeps the joint lubricated is depleted. The lack of lubrication can cause so much wear and tear as to cause significant pain and reduced mobility in the patient.
Our therapies replace the lubricating and shock-absorbing properties of the synovial fluid. Our treatments insert hyaluronic acid (an important ingredient in synovial fluid) directly into the joint, restoring the synovial fluid to its former strength. Not only does this provide long-term pain relief that can lasts for months, but the new lubrication also helps to further reduce joint pain. Our joint injection therapies can be administered right in the physician’s office, without the need for hospital visits.
Discover how our joint therapies are the solution osteoarthritis patients need.
Learn more about GELSYN-3 , SUPARTZ FX , and DUROLANE .
Bioventus Surgical understands the extraordinary potential of orthobiologics in bone formation. We are solely focused on orthobiologic product performance and are committed to deliver best-in-class solutions that meet the requirements of surgeons and their patients, across a broad range of risk factors, procedures, and hardware selection.
Our comprehensive portfolio incorporates a science based approach to deliver key elements for bone formation in an optimal environment. Learn more about our Allograft, Cell & Marrow, and Synthetic offerings.
Learn more about our products:
- Nolte PA, van der Krans A, Patka P, Janssen IM, Ryaby JP, Albers GH. Low-intensity pulsed ultrasound in the treatment of nonunions. J Trauma. 2001;51(4):693-703.
- Schultz M, Oremus M, Whitman CS, Conway JD. Cost-effectiveness of bone stimulators in the conservative treatment of stable non-union fractures. International Society for Pharmacoeconomics and Outcomes Research, Seventh Annual European Congress, Hamburg, Germany, Oct. 24-26, 2004.
*EXOGEN Summary of Indications for Use: The EXOGEN Ultrasound Bone Healing System is indicated for the non-invasive treatment of established non-unions† excluding skull and vertebra. In addition, EXOGEN is indicated for accelerating the time to a healed fracture for fresh, closed, posteriorly displaced distal radius fractures and fresh, closed or Grade I open tibial diaphysis fractures in skeletally mature individuals when these fractures are orthopaedically managed by closed reduction and cast immobilization.
There are no known contraindications for the EXOGEN device. Safety and effectiveness has not been established for individuals lacking skeletal maturity; pregnant or nursing women; patients with cardiac pacemakers; on fractures due to bone cancer; or on patients with poor blood circulation or clotting problems. Some patients may be sensitive to the ultrasound gel. Full prescribing information can be found in product labeling, at www.exogen.com or by contacting customer service at 1-800-396-4325.
†A non-union is considered to be established when the fracture site shows no visibly progressive signs of healing.
SUPARTZ FX is indicated for treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen. You should not use SUPARTZ FX if you have infections or skin diseases at the injection site or allergies to poultry products. SUPARTZ FX is not approved for pregnant or nursing women or children. Risks can include general knee pain, warmth and redness at the injection site. Full prescribing information can be found in product labeling, at www.SUPARTXFX.com or by contacting customer service at 1-800-396-4325.
DUROLANE indications vary by market, but include the following: Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved in the EU for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers, toes and temporomandibular and facet joints. DUROLANE is also indicated for pain following joint arthroscopy either in the presence of osteoarthritis or subsequent to general surgical repair within 3 months of the procedure.
There are no known contraindications. You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. Risks can include transient pain, swelling and/or stiffness at the injection site. Full prescribing information can be found in product labeling, at www.durolane.com or by contacting customer service at 1-800-396-4325.
